<div id="readability-page-1"><p>Annex Advisory Services LLC lowered its holdings in  Stryker Corporation (NYSE:SYK - Free Report) by 87.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor  owned 2,245 shares of the medical technology company's stock after selling 15,163 shares during the period. Annex Advisory Services LLC's holdings in Stryker were worth $789,000 as of its most recent filing with the Securities and Exchange Commission.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>A number of other hedge funds have also added to or reduced their stakes in SYK. Clayton Financial Group LLC bought a new position in  Stryker in the third quarter valued at $26,000.  United Financial Planning Group LLC bought a new position in  Stryker in the third quarter valued at $27,000.  Strive Asset Management LLC bought a new position in  Stryker in the third quarter valued at $30,000.  ANTIPODES PARTNERS Ltd bought a new position in  Stryker in the third quarter valued at $34,000.  Finally, Copia Wealth Management grew its position in  Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own  77.09% of the company's stock. </p><h2>Insiders Place Their Bets</h2><p>In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders. </p><h2>Stryker Price Performance</h2><ul><li>Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?</li></ul><p>Shares of Stryker stock opened at $341.74 on Thursday. Stryker Corporation has a twelve month low of $319.32 and a twelve month high of $404.87. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The company has a 50-day simple moving average of $353.78 and a two-hundred day simple moving average of $359.95. The stock has a market capitalization of $130.88 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 2.02 and a beta of 0.92. </p><p>Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to analysts' expectations of $7.12 billion. During the same quarter in the previous year, the company earned $4.01 EPS. The business's revenue was up 11.4% on a year-over-year basis.  Analysts forecast that  Stryker Corporation will post 13.47 EPS for the current year. </p><h2>Stryker Announces Dividend</h2><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul><p>The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's payout ratio is 41.90%. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts recently weighed in on SYK shares. Citizens Jmp raised shares of Stryker from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $440.00 target price for the company in a research report on Friday, December 19th. Sanford C. Bernstein raised their target price on shares of Stryker from $450.00 to $465.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday, January 9th. William Blair  reissued an &#34;outperform&#34; rating on shares of Stryker in a research report on Thursday, March 5th. Weiss Ratings  reissued a &#34;hold (c+)&#34; rating on shares of Stryker in a research report on Monday, December 22nd. Finally, Barclays  reissued an &#34;overweight&#34; rating and issued a $469.00 price objective on shares of Stryker in a research report on Monday, February 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $421.11.</p><p><b>Read Our Latest Research Report on Stryker</b></p><h2>Key Headlines Impacting Stryker</h2><p>Here are the key news stories impacting Stryker this week:</p><ul>   <li><span>Positive Sentiment: </span>Stryker agreed to acquire Amplitude Vascular Systems to add next‑generation IVL technology, expanding its peripheral vascular offerings and potentially accelerating addressable market growth in arterial disease — a strategic tuck‑in that investors generally view as growth‑accretive. <i></i><span>Stryker to Acquire AVS (Zacks)</span></li>    <li><span>Positive Sentiment: </span>BTIG reaffirmed a Buy rating and set a $397 price target, signaling continued analyst confidence in Stryker's growth and supporting upside expectations for the stock. <i></i><span>BTIG Buy Reaffirmed</span></li>    <li><span>Positive Sentiment: </span>Leerink Partners initiated coverage on Stryker with an outperform/recommendation, adding another supportive institutional view that may help underpin the stock over time. <i></i><span>Leerink Initiates Coverage (MSN)</span></li>    <li><span>Neutral Sentiment: </span>A separate initiation notice was posted by AmericanBankingNews; initiation increases institutional coverage and liquidity but its immediate directional impact depends on the report's stance and investor reaction. <i></i><span>Leerink Initiates Coverage (AmericanBankingNews)</span></li>    <li><span>Negative Sentiment: </span>Truist lowered its price target from $395 to $380 and moved to a &#34;hold&#34; rating, reducing the implied upside and contributing to near‑term selling pressure as some investors mark positions to the lower PT. <i></i><span>Truist Lowers Price Target (Benzinga)</span></li> </ul><h2>Stryker Company Profile</h2> (Free Report)<p>Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Stryker</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Stryker Right Now?</h2><p>Before you consider Stryker, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Annex Advisory Services LLC has significantly reduced its holdings in Stryker Corporation (NYSE:SYK) by 87.1%, selling 15,163 shares in the fourth quarter. Following the sale, they now own 2,245 shares valued at $789,000. Other institutional investors have also adjusted their stakes in Stryker. Additionally, Director Ronda E. Stryker sold 250,000 shares for approximately $90.73 million. Stryker's stock opened at $341.74, with a market cap of $130.88 billion and a recent quarterly earnings report showing a net margin of 12.92%. The company announced a quarterly dividend of $0.88, payable on April 30.</p>

Market Beat

Stryker

iShares US Medical Devices

Annex Advisory Services LLC Sells 15,163 Shares of Stryker Corporation $SYK